Press Releases | Medtronic

Month Year

Email alerts

Dec 3, 2018

Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial

Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation

DUBLIN - December 3, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient treated in the TERMINATE AF trial, a multi-center study evaluating two surgical ablation devices - the...
Nov 21, 2018

Medtronic to Acquire Nutrino Health

Acquisition to Augment Diabetes Capabilities with Nutritional Database and Data Science

DUBLIN and TEL AVIV, Israel - November 21, 2018 - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Nutrino Health Ltd., a leading provider of nutrition-related data services,...
Nov 20, 2018

Medtronic Reports Second Quarter Financial Results

Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic

DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second...
Nov 16, 2018

New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System

Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies

DUBLIN and NEW YORK - November 16, 2018 - Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients...
Nov 13, 2018

Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System

Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease

DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of...
Nov 9, 2018

Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019

DUBLIN - November 9, 2018 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release...
Nov 8, 2018

Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension

DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal...
Nov 8, 2018

Medtronic Delivers Significant Progress on Global Corporate Citizenship Efforts

2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals

DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, is pleased to announce its fiscal year 2018 (FY18) Integrated Performance Report. The 2018 Integrated...
Nov 6, 2018

Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials

(GLOBE NEWSWIRE via COMTEX) --New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

DUBLIN and LAS VEGAS - November 6, 2018 - Medtronic plc (NYSE:MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB)...
Oct 24, 2018

FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain

(GLOBE NEWSWIRE via COMTEX) --myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician DUBLIN - October...

Show per page